RT Journal Article
SR Electronic
T1 Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network
JF CMAJ Open
JO CMAJ
FD Canadian Medical Association
SP E610
OP E617
DO 10.9778/cmajo.20190103
VO 7
IS 4
A1 Carla S. Coffin
A1 Alnoor Ramji
A1 Curtis L. Cooper
A1 David Miles
A1 Karen E. Doucette
A1 Philip Wong
A1 Edward Tam
A1 David K. Wong
A1 Alexander Wong
A1 Sylvester Ukabam
A1 Robert J. Bailey
A1 Keith Tsoi
A1 Brian Conway
A1 Lisa Barrett
A1 Tomasz I. Michalak
A1 Stephen E. Congly
A1 Gerald Minuk
A1 Kelly Kaita
A1 Erin Kelly
A1 Hin Hin Ko
A1 Harry L.A. Janssen
A1 Julia Uhanova
A1 Brendan C. Lethebe
A1 Sarah Haylock-Jacobs
A1 Mang M. Ma
A1 Carla Osiowy
A1 Scott K. Fung
A1 ,
YR 2019
UL http://www.cmajopen.ca/content/7/4/E610.abstract
AB Background: Published Canadian epidemiologic data on hepatitis B virus (HBV) infection include single-centre studies or are focused on Indigenous populations. We performed a study to characterize the demographic and clinical features, liver disease status and treatment of people with chronic hepatitis B in Canada.Methods: In this descriptive, opportunistic, cross-sectional study, available data for people known to be monoinfected with HBV were collected by the Canadian HBV Network from existing clinical databases (2012-2019), with support from the National Microbiology Laboratory, Public Health Agency of Canada. Data were collected in all provinces with the exception of New Brunswick and Prince Edward Island. We analyzed the data using parametric and nonparametric statistical methods, with a significance level of p < 0.05.Results: In the 9380 unique patient records reviewed, the median age was 48 years, and 5193 patients (55.4%) were male. Ethnicity information was available for 7858 patients, of whom 5803 (73.8%) were Asian, 916 (11.6%) were black and 914 (11.6%) were white. Most of those tested (5556/6796 [81.8%]) were negative for HBV e-antigen, and most of those with fibrosis data (3481/4260 [81.7%]) had minimal liver fibrosis, with more advanced fibrosis noted in older people (> 40 yr). Of the 980 patients with genotype data, 521 (53.2%) had genotype B or C infection. Most of the 9241 patients with known confirmed treatment status received tenofovir disoproxil fumarate (1655 [17.9%]), lamivudine (1434 [15.5%]) or entecavir (548 [5.9%]).Interpretation: Based on available data, Canadian patients with chronic hepatitis B are predominantly Asian and negative for HBV e-antigen, and have genotype B or C infection. Interprovincial variations were noted in antiviral treatment regimen. This multicentre nationwide study provides data regarding patients with chronic hepatitis B and may inform future studies on the epidemiologic features of HBV infection in Canada.